Market Overview

Familial Adenomatous Polyposis Coli - Pipeline Insight, 2018 - ResearchAndMarkets.com

Share:

The "Familial
Adenomatous Polyposis Coli - Pipeline Insight, 2018"
drug
pipelines has been added to ResearchAndMarkets.com's
offering.

'Familial Adenomatous Polyposis Coli - Pipeline Insight, 2018' report
offers comprehensive Insight of the pipeline (under development)
therapeutics scenario and growth prospects across Familial Adenomatous
Polyposis Coli development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Familial Adenomatous Polyposis Coli Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

  • Cancer Prevention Pharmaceuticals Inc
  • Marina Biotech Inc
  • Thetis Pharmaceuticals LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l6wblv/familial?w=4

View Comments and Join the Discussion!